Bavarian Nordic owns a broadly applicable MVA-BN® vaccine platform technology, which can be applied to develop multiple vaccines across various disease areas, tested in more than 3,400 persons. We can offer out-licensing opportunities of our proprietary technologies and/or vaccine programmes and we search for innovative technologies supplementing our in-house technologies and programmes. We are also interested in research collaborations with academic groups and biotech companies. We might be able to provide technologies and production know-how that your organization can use to explore scientific arenas that lay beyond your available resources and skills.
ASCO Annual Meeting
June 1-5, 2012 Chicago, USA http://chicago2012.asco.org/
2012 BIO International Convention
June 18-21, 2012 Boston, USA convention.bio.org
European Pharma Licensing Symposium
September 17-19, 2012 Budapest, Hungary
